gained popularity. Despite their advantages, however, JVs present significant challenges and many fail to deliver expected
value from shared initiatives abroad, resulting in demand for increased scrutiny,
OM policies, enacted governance. and
restructuring of deal terms. This, in turn,
is driving demand for more ongoing and
cyclical advisory that realigns agreements
in light of market realities to evolve into
more viable joint ventures.
The spectrum of partnership and combined arrangement types is broad and
drives varying levels of shared platforms,
legal, financial, tax and regulatory implications ‒ resulting in a plethora of complexity and variability. Consulting expertise
is evolving that supports “mixed model”
partnerships among HC and LS organizations, from financial and operating metrics
to population health insights that inform
portfolio strategies and link partnership
opportunities with HC system incentives.
Accelerated pace to partner and test
the water—now is the time. Innovations
in drug development and research, pa-
tient treatments, care delivery models, and
HC information management continues
to transform HC/LS consulting capabil-
ities. As JVs, partnerships and collabora-
tions serve as growth agendas and testing
grounds for further expansion, the pace
and scope of partnerships are proliferating,
with traditional and new market entrants
laying claim to best-of-breed partners.
This is driving firms to develop competen-
cies that guide clients through comprehen-
sive partnership strategy lifecycles.
For more information on this research report, please
Liz Leonard is an Associate Director, Lead for Healthcare
Consulting Research. Her focus is on consulting in the
healthcare marketplace, including coverage on payers,
providers, life sciences, and biotechnology areas.
Source: Consulting to the Healthcare Industry; Kennedy Consulting Research & Advisory
HC/LS JV AND